Vilon

Vilon's proposed mechanism follows the Khavinson three-stage framework applied to the simplest-possible peptide. Stage one is absorption: oral Vilon is claimed to be absorbed intact from the gut because it is small enough (275 Da) to cross the intestinal epithelium without active transport, though some published pharmacokinetic work has suggested that peptidase cleavage at this level of simplicity is substantial, so only a fraction of the administered dose reaches systemic circulation as intact dipeptide. Stage two is distribution and nuclear import: Vilon is claimed to distribute preferentially to thymus, bone marrow, lymphoid tissue, and peripheral lymphocytes, passively crossing cell and nuclear membranes. Stage three is sequence-selective DNA interaction: the dipeptide is claimed to bind specifically to promoter regions of immune-relevant genes, influencing transcription of proteins involved in T-cell maturation, cytokine production, and thymus-dependent immune function (Khavinson, 2011).

The sequence-selective DNA binding claim is most controversial for Vilon specifically because the peptide has only two residues. A dipeptide has very limited surface area for DNA contacts. Classical sequence-specific DNA-binding domains in transcription factors typically use 10 to 20 amino acids of ordered structure to make their contacts. Khavinson has argued that the dipeptide's electrostatic character (positive lysine and negative glutamate) still produces preferential interaction with certain DNA sequences, and that the resulting binding, while weaker and less specific than a classical transcription factor, is sufficient to nudge gene expression in aged cells where the existing regulatory machinery is already fraying. This is an unusual argument in mainstream molecular biology and has not been replicated at the level of rigor required to be settled science.

Independent of the sequence-selective DNA binding question, Vilon's observed effects in Khavinson-group work have been documented at three levels.

At the thymus level, Vilon is claimed to support residual thymic function in older adults. Thymic involution begins in early adulthood and continues throughout life; by the sixth decade, thymic tissue has largely been replaced by adipose tissue, though a small cortical-medullary structure remains with reduced but non-zero naive T-cell output. Khavinson's group has reported that Vilon cycling supports this residual thymic output, as measured by signal-joint T-cell receptor excision circle (sjTREC) quantification in peripheral blood and by CD4 and CD8 naive T-cell subset counts. The signal reported is modest and not consistently replicated in Western studies.

At the peripheral T-cell level, Vilon is claimed to influence CD4/CD8 ratio, support Th1/Th2 balance in older adults tending toward Th2 dominance, and improve T-cell proliferative response to mitogens. Again, the reported effect sizes are modest and are derived from small cohorts without placebo controls.

At the NK cell and innate immunity level, Vilon is claimed to support natural killer cell cytotoxicity, which declines with age and contributes to cancer surveillance. A modest NK cytotoxicity enhancement after cycling has been reported in Khavinson-group observations. The clinical meaning of such a modest change in terms of actual cancer risk, infection susceptibility, or immune outcomes is not established.

Vilon is also claimed to modulate hematopoiesis more broadly, supporting bone marrow function and peripheral blood cell counts. The evidence is thin and has not been extended to hematologic indications in any rigorous way.

Beyond the Khavinson framework, some theoretical mechanisms are worth noting for context. Lysine and glutamate are both amino acids with established nutritional and metabolic roles. Lysine is an essential amino acid important for collagen synthesis, carnitine synthesis, and a precursor of glutamate metabolism. Glutamate is a ubiquitous metabolic intermediate and the major excitatory neurotransmitter. Oral Lys-Glu dipeptide in milligram quantities does not substantially change systemic lysine or glutamate availability. The proposed bioregulator effect of Vilon is therefore not attributable to amino acid nutrition; it relies on the more specific (and more speculative) claim that the intact dipeptide exerts regulatory effects on gene expression.

A physiologically important caveat: gut absorption of intact dipeptides is real and well characterized. The PEPT1 transporter in small intestine absorbs di- and tripeptides directly without cleavage to free amino acids, which is why oral peptide bioavailability for short peptides is generally better than for tetra- and pentapeptides. Vilon's oral bioavailability as intact dipeptide is therefore plausible at the level of getting into systemic circulation. What happens after absorption — whether the intact dipeptide reaches the thymus, enters lymphocytes, crosses nuclei, and binds DNA at meaningful concentrations — is the contested part.

For a reader evaluating Vilon, the practical takeaway is: the proposed mechanism is coherent with what is known about immune aging and with basic peptide pharmacology. If Vilon produces a real but modest effect on thymus-dependent immune output or NK cell activity, the contribution stacks on top of vaccination and lifestyle without replacing them. If Vilon does not produce a meaningful effect in humans — which the limited evidence base cannot rule out — then placebo and Hawthorne effects may explain most reported benefit. Either way, a reader should not expect Vilon to substantially restore youthful immune function or to substitute for established immune interventions (vaccination, treatment of chronic disease, avoidance of immune-suppressing exposures).

Vilon is the simplest member of Vladimir Khavinson's short-peptide bioregulator catalog — a dipeptide of lysine and glutamic acid (H-Lys-Glu-OH, abbreviated KE). Developed at the Saint Petersburg Institute of Bioregulation and Gerontology in the late 1990s as a synthetic follow-on to the first-generation thymus polypeptide extracts (Thymalin, Thymogen), Vilon was positioned as a minimal-sequence immune and thymic bioregulator. Within the broader Khavinson catalog — Epitalon, Thymogen, Pinealon, Livagen, Bronchogen, Cardiogen, Cartalax, Chonluten, Ovagen, Testagen, Prostamax, and Vesugen — Vilon occupies a foundational position. It is the first compound in the short-peptide line and the one most consistently cited across Khavinson's theoretical framework because its extreme structural simplicity makes it the cleanest test case for his sequence-selective DNA binding and tissue-specific gene modulation claims.

Commercial Vilon is sold as an oral capsule in Russia and Eastern European markets. The standard 20 mg nominal capsule contains approximately 2 to 4 mg of synthetic peptide dispersed in milk-protein and starch excipients — the same formulation strategy used across the Khavinson capsule line. It is also available in some markets as a subcutaneous lyophilized peptide for injection. Vilon is not a registered pharmaceutical in the United States, the European Union, the United Kingdom, Canada, or Australia. It is not FDA-approved for any indication. It is sold as a research chemical or as an over-the-counter supplement depending on jurisdiction.

The Khavinson literature positions Vilon as a broad-spectrum immune modulator with reported effects on thymus-derived lymphocyte maturation, peripheral T-cell subset balance, natural killer cell activity, and age-related immune decline. Because lysine and glutamate are both charged amino acids (Lys positive, Glu negative) and because the dipeptide has only two peptide-bond-linked residues, Khavinson has argued that Vilon represents the minimum recognizable unit of his tissue-selective DNA binding model. The theoretical claim is that a two-residue ligand can still make enough electrostatic and hydrogen-bonding contacts with specific DNA sequences to influence transcription at particular promoters — a stronger assertion than most Western molecular biology would comfortably accept, but foundational to the Khavinson framework.

BodyHackGuide treats Vilon honestly rather than promotionally. All human clinical evidence for Vilon is from small observational studies from Khavinson's group and a limited set of Russian and Eastern European collaborators. Independent Western replication is sparse. The claim that a synthetic dipeptide of this simplicity produces reproducible, tissue-specific, clinically meaningful effects on human immune function is not established by the evidence standards that Western regulators require for therapeutic approval. Readers evaluating Vilon for immune support should compare it to vaccination, evidence-based chronic disease management (diabetes, obesity, hypertension control, all of which modulate immune function), sleep tuning, exercise, and micronutrient sufficiency (vitamin D, zinc, selenium) — all of which have substantially stronger evidence for supporting immune outcomes than any Khavinson peptide.

The main demographic buying Vilon is older adults concerned about age-related immune decline (immunosenescence). The biology of immunosenescence is real and well characterized — thymic involution over the lifespan, reduced naive T-cell output, diminished T-cell receptor repertoire, impaired vaccine responses, reduced NK cell cytotoxicity, increased susceptibility to infection, and increased incidence of cancer with age. The question is whether a synthetic dipeptide cycled twice a year can produce clinically meaningful mitigation of those changes. The Khavinson framework argues yes; mainstream immunology reserves judgment. A reader considering Vilon for age-related immune concerns should layer it onto a solid foundation — annual influenza vaccination, recommended COVID-19 boosters, pneumococcal vaccination at appropriate ages, shingles vaccination, routine cancer screening, lifestyle tuning — rather than relying on it as a primary immune strategy.

A secondary demographic is users interested in Khavinson's broader anti-aging framework. Vilon is often cycled alongside Epitalon in anti-aging stacks, with the theoretical justification that Epitalon acts on the pineal gland (circadian, telomerase) while Vilon acts on the thymus (immune, T-cell). The paired-axis framing is central to Khavinson's "pineal-thymic" model of aging, in which declining pineal and thymic function are proposed as interlocked drivers of systemic aging. Whether that framework is accurate at the level of clinical intervention is an open question; the framework itself is coherent at the level of observation that both organs undergo age-related involution.

Vilon is most commonly cycled as 1 or 2 oral capsules daily on an empty stomach for 10 consecutive days, followed by a 60 to 90 day washout, with 2 to 4 cycles per year. Injectable Vilon follows a similar pattern at doses of 50 to 200 mcg subcutaneously daily during an active cycle. Users frequently layer Vilon with Thymogen for immune goals, with Epitalon for anti-aging goals, or with Pinealon for cognitive-immune overlap.

Safety observation in the published Khavinson work has been consistently reassuring at the oral doses used. Because Vilon is structurally very simple (a dipeptide, 275 Da molecular weight), and because lysine and glutamate are standard dietary amino acids, acute toxicity at the microgram-to-milligram doses used is essentially zero. The tolerability is similar to taking a very small amount of a dipeptide that already occurs in partial proteolytic digests of any dietary protein. Theoretical concerns specific to Vilon include hypothetical unintended immune activation (not observed in practice but possible), hypothetical interaction with immunosuppressive therapy (not characterized in published data), and the general concern applicable to all Khavinson peptides that the published evidence base is too small to detect rare serious adverse events. A reader on active immunosuppressive therapy (post-transplant, active autoimmune disease on biologics, active cancer therapy) should not initiate Vilon without their specialist's input.

The honest positioning on this page: Vilon is the simplest and longest-studied Khavinson peptide, with a modest amount of Russian clinical observational data supporting tolerability and suggesting weak-to-moderate immune-modulatory effects. It is not a replacement for vaccination, evidence-based lifestyle management of chronic disease, or disease-specific immune therapies where indicated. It can be considered as an experimental adjunct for users who want to explore the Khavinson bioregulator framework with the minimum-complexity reference peptide.

IUPAC Name

L-Lysyl-L-glutamic acid

CAS Number

90203-91-1

Molecular Formula

Lys-Glu

Molecular Mass

261.27 g/mol

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Interaction Matrix

Get Vilon Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Related Compounds

Data Completeness

Research Credibility